Development and Preclinical Testing of a Novel Neurodenervant in the Rat: C3 Transferase Mitigates Botulinum Toxin’s Adverse Effects on Muscle Mechanics
Spasticity, characterized by elevated muscle tone, is commonly managed with botulinum toxin type A (BTX-A). However, BTX-A can paradoxically increase passive muscle forces, narrow muscles’ length range of force exertion (l<sub>range</sub>), and elevate extracellular matrix (ECM) stiffnes...
Saved in:
| Main Authors: | Cemre Su Kaya Keles, Zeynep D. Akdeniz Dogan, Can A. Yucesoy |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-05-01
|
| Series: | Toxins |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6651/17/5/234 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Recombinant botulinum toxin as a new stage in the development of botulinum toxin therapy. Possibilities and perspectives of use in neurological practice
by: R. K. Shikhkerimov, et al.
Published: (2022-12-01) -
Botulinum toxin treatment of lower extremity spasticity
by: S. E. Khat’kova, et al.
Published: (2017-11-01) -
Switox: Retrospective Analysis of Botulinum Toxin Switching in Management of Spasticity
by: Emilie Leblong, et al.
Published: (2025-02-01) -
Ultrasound-Guided Botulinum Toxin Injections for Hand Spasticity: A Technical Guide for the Dorsal Approach
by: Calogero Malfitano, et al.
Published: (2025-05-01) -
Research progress in the use of botulinum toxin type a for post-stroke spasticity rehabilitation: a narrative review
by: Qianwen Xu, et al.
Published: (2025-12-01)